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ABSTRACT 
Acquired Immunodeficiency Syndrome (AIDS) caused by Human 
Immunodeficiency Virus (HIV). The postmortem examination room is 
the place where infection can spread to persons who are performing 
autopsy. These personnels are having high risk of various injuries, 
infections. Forensic personnels who are involved in examination of 
homosexuals and drug abusers, are having great chance of being infected 
by HIV than common people. We conducted the Study to find the 
incidence of HIV in routine autopsy cases.  
 
Materials and methods: The study sample consists of 486 routine 
autopsy cases at Rajiv Gandhi Government General Hospital. The 
samples were tested using an enzyme immunoassay using SD Bioline 
HIV1/2 3.0 Rapid test kits to detect the presence of HIV-1 and HIV-2 
antibodies. Samples yielding reactive results were confirmed by Alere 
DetermineTM HIV 1/2 method which detects HIV-1, HIV-2 antibodies.  
 
Conclusion: Out of 486 subjects in this study group, 4 cases were 
positive for HIV and all were previously unknown seropositive cases. 
This shows that HIV screening is of great importance among the 
community where the crime rate is high. Homicide victims in our study 
showed a relatively higher prevalence of HIV-1, infections compared 
with other manners of deaths. 
 
 
 
 
 
INTRODUCTION 
Acquired Immunodeficiency Syndrome (AIDS) caused by Human 
Immunodeficiency Virus (HIV). HIV is a disorder of the immune system 
in which there is a breakdown of defense mechanism against infection, 
which leaves the person susceptible to the life-threatening infectious 
diseases including unusual malignancies.1 
It is estimated that about 14,000 HIV infections occur every day 
around the world approximately and out of these, 90% of these are in 
developing countries2. HIV is of two types namely HIV-1 and HIV-2, 
both of these viruses can cause manifestations, which cannot be 
distinguished from each other. The difference remains in the onset of the 
disease; HIV-2 has a delay in onset of disease3. Universally, infections 
rates are maximum in sub-Saharan Africa and are also are high in 
southeast Asia.4 
The postmortem examination room is the place where infection can 
spread to persons who are performing autopsy. These personnels are 
having high risk of various injuries, infections.5,6 Forensic personnels 
who are involved in examination of homosexuals and drug abusers, are 
having great chance of being infected by HIV than common people. 
Forensic experts are exposed not only to scalpels, needles but also to the 
bones, body fluids and tissues of dead bodies every day8. 
 
 
 
Autopsy safety was not of much attention till 1980, it was taken in 
to consideration only when HIV infection appeared8. Testing for HIV in 
the autopsy room has not been done routinely because samples to be 
tested need a special equipped laboratory, well trained technician and also 
more time is needed to obtain the results. Therefore a simple, reliable and 
rapid means for detecting the antibodies to HIV infection is needed and 
this can be useful for screening in the autopsy rooms9. Since there are no 
clear strategies as when a deceased body should no longer be considered 
infectious.9 
Only limited data is available regarding the occupational 
transmission of the HIV from the corpses to the persons who engaged 
directly or indirectly in the autopsy procedures and other individuals who 
handle the dead bodies of various stages of decomposition10. The purpose 
of this study is to determine whether autopsies of the corpses, which have 
been presumed to be low risk groups, are safe or not. Thus, we conducted 
a study to identify the seroprevalence of these viruses in a low risk 
forensic autopsy population. 
Testing HIV antibodies during autopsies has been useful not only 
for assessing the risk to the mortuary workers but also useful for the 
epidemiological studies11. Many simple, rapid and reliable tests for 
detecting the antibodies are needed for reducing occupational health 
 
 
 
hazards in the mortuary, because the HIV may survive for several days in 
the postmortem samples. The applicability of the tests for detecting 
antibodies to HIV in autopsy samples depends on the postmortem 
stability of the antibodies as well as on the sensitivity of the screening 
tests12. 
In a population, where there is a low HIV prevalence, refusals from 
screening for HIV tests by the people with risk behavior may occur and 
this strongly bias the seroprevalence. The social habits, human ethical 
issues and religious customs becomes an obstacle to obtain the 
information about the dead bodies13,14. 
Autopsy screening efficiently reveals the true incidence in groups 
where refusal may be common. This study enables to identify HIV status 
of the deceased whose HIV status was unknown previously because it is 
not practical or cost-effective to take full universal precaution with every 
autopsy.14 
 
 
 
 
AIMS AND OBJECTIVES 
 
1. To Study the incidence of HIV in routine autopsy cases. 
2. To create awareness among the doctors doing postmortem and the 
mortuary workers. 
3. To diagnose the clinically undetected   HIV cases. 
4. To determine whether postmortem of deadbodies which are 
thought to be at low risk groups, are safe or not. 
5. To formulate guidelines for a policy concerning HIV antibody 
screening in forensic autopsy cases 
6. To determine how much autopsies are safe in relation to pre-
autopsy testing for HIV. 
7. To identify the seroprevalence of HIV in autopsy room personnels. 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
The situation of Forensic Pathologists to perform autopsies in cases 
whose HIV status is not known prior to autopsy. A person infected with 
HIV may die of an unrelated cause, in those individuals there is no clear-
cut evidence of HIV status. HIV incidence is the measure of new cases in 
a given period of time. This occurrence of new cases helps us to supervise 
HIV epidemic in the country. This information also helps us to create or 
modify the awareness programme to educate the general population and 
high risk community who are vulnerable to HIV infection. 
HIV antibodies testing in autopsies have been valuable for 
epidemiological purposes15, 16. Consistent tests may also be needed to 
reduce the occupational health hazards in the mortuary, because the HIV 
may survive for several days in postmortem samples17. 
The applicability of the tests for detecting HIV antibodies in 
autopsy samples depends on the postmortem stability of the antibodies as 
well as on the sensitivity of the screening test. The globulins that contain 
antibodies  are not affected by postmortem autolysis, or bacterial 
contamination 18. 
Medico legal autopsies include fatal traffic accidents and sudden 
death, which is considered to provide the most representative sample of 
 
 
 
the living population. Moreover, homosexuals and drug addicts with a 
high HIV-infection risk often commit suicide or otherwise die violently 
and are thus subjected to medico legal autopsy19. Hence, HIV-testing in 
medico legal autopsies would be a valuable method in searching for 
'hidden' HIV carriers 20, 21. 
When the forensic pathologists conduct postmortem on dead-
bodies that are in various stages of decomposition, a thorough autopsy of 
the soft tissue and skeleton is necessary to come to a conclusion regarding 
the identity and cause of death especially in suspicious cases22. 
Irrespective of the stage of decomposition, the chance of exposure to 
various infectious organisms in the body fluids and tissues is very high. 
An exposure to HCW (Health care worker) at risk of HIV is defined as a 
needle-stick or cut in the connective tissue by sharp instruments, 
exposure to mucosa or contact with intact or cut skin when the period of 
exposure is extended23. 
The studies conducted prospectively have assessed that 
approximate risk of infection by HIV after a percutaneous needle injury is 
at a rate of 0.3%24. In the context of an autopsy it is important that not 
only blood but also other body fluids that are highly infectious like 
amniotic fluid, pleural fluid, seminal fluid, pericardial fluid, peritoneal 
fluid, vaginal fluid and cerebrospinal fluid. 
 
 
 
Weston and Lober et al. have recognized that rupture of the 
surgical glove occurs in about 9% of autopsy. About 33% of glove 
puncture goes undetected by the pathology personnels, which can expose 
the previous injury in the hand to come in contact with infected blood for 
a long time25. 
Coleman, D.L. Luce et al (1986)26 conducted a study to detect 
antibodies to the Retrovirus in presumably healthy San Franciscans who 
died unexpectedly. Of the 121 samples tested for antibodies to HIV, 23 
cases were positive for HIV which was very high than other voluntary 
screening programs, which shows that abstaining the high risk individual 
from testing may cause serious errors in all kinds of voluntary 
surveillance programs. 
Schoub, B. D., Johnson, et al (1989)27 conducted a study to detect 
the HIV seropositivity in sera from medico legal autopsies in 
Johannesburg, out of the 745 samples tested 6 (0.8%) were positive for 
HIV antibodies. 
Dupon, M., Bonnici, et al (1989)28 in his study Screening for HIV 
in Necropsies, of the 114 samples tested for HIV antibodies in the city of 
Bordeaux 5(4.6%) samples were reactive. 
 
 
 
Klatt et al (1989) assessed the reliability of postmortem enzyme 
immunoassay testing for antibodies to HIV and determined that vitreous 
humor is reliable for testing antibodies to HIV up to 34 hours postmortem 
and blood atleast up to 58 days were frequently positive for HIV. He 
concluded that Postmortem enzyme immunoassay testing of vitreous 
humor blood and may be valuable to screen for screening HIV infection 
in high-risk groups.40 
Little and Ferris et al (1990)29 Tested for the presence of 
antibodies to HIV in Forensic autopsies at Vancouver, using the 
recombinant immunoblot assay (RIBA) technique. 207 forensic autopsy 
cases were tested for the HIV antibodies. Out of which, 172 persons were 
without any known history of HIV. In this only 2 cases were positive for 
HIV, but the results were not confirmed by further testing. The RIBA 
HIV test system has 100% sensitivity and 98.5% specificity. However 
this procedure is time consuming and this requires special equipment so it 
is not suitable for routine diagnosis for autopsy screening. 
Karhunen, et al (1992)14 Detected the HIV antibodies in medico 
legal autopsies using an enzyme immunoassay on postmortem sera was 
conducted for a period of 5 years. This study consist medicolegal 
autopsies of all deaths under the age of 65 years and the study sample was 
7305. Out of which nine (0.12%) were positive for HIV. 7 of these cases 
 
 
 
were previously known case of HIV and remaining 2 were unknown. He 
concluded that testing of HIV in medico legal autopsies helps in 
identifying the new cases of HIV. These HIV testing have no ethical 
issues and may be sensitive to early changes in epidemiology.14 
David Sadler et al (1992)30 studied the prevalence of HIV 
antibodies using ELISA in the 500 postmortem samples to detect the 
antibodies to both HIV1 and HIV2, the positive results were confirmed 
by second ELISA. He classified the individual in to risk and no known 
risk individual based on the history from police, practitioner and from 
hospital records. He concluded that autopsy population contains high risk 
individual, therefore testing for HIV antibodies in these individuals is 
useful epidemiologically. 
Kringsholm, et al (1993)31 Studied the incidence of HIV-1 
antibodies among 389 individuals who are addicted to drugs. The study 
was conducted in a medical institution at Copenhagen. The incidence of 
HIV 1 was almost equal in both male and female. In around one third of 
the HIV-1-positive cases, the HIV status was not known previously. 
Therefore he concluded that in autopsied drug addicts the diagnosis of 
HIV-1-infection is significant for epidemiological data and also for safety 
measures. 
 
 
 
Li, Zhang, Constantine et al (1993)32 Studied the Seroprevalence 
of HBV, HCV, HIV-1 in forensic autopsy, using ELISA to analyze the 
risk factors connected with it. A total of 414 serum samples were tested 
for HBV, HCV, HIV-1, HTLV-I and HTLV-II antibodies in autopsy 
cases successively. Of the 414 cases, about 6% were positive for HIV-1, 
19.1% for HCV, 23.2% for HBV, and 1.0% for HTLV-I and HTLV-II. 
He established that the overall HIV 1 prevalence was greater than the 
general population at Maryland. Routine testing only for HIV-1 may miss 
other infections like hepatitis C virus or hepatitis B virus. This study 
recommends universal precautions for all autopsy cases. 
Lockemann et al (1993)33 studied the HIV-status of 3999 autopsy 
cases from 1989-1992 at Hamburg. All the autopsy cases included in the 
study were with unnatural death and the cause of death was not known. 
Primarily HIV was tested by Enzyme Linked Immuno Sorbant Assay and 
confirmed by Western-blot. Confirmation was done in 55 positive cases 
using Western-blot. The seroprevalence of HIV was 1.4%. He concluded 
that Serological HIV-testing of drug associated deaths helps in 
epidemiology screening among high-risk group. 
Douceron and Deforges et al (1993)34 conducted the study to 
carry out the postmortem safely without the risk of infection by HIV. In 
this study, they cultured the blood serially for a variable postmortem 
 
 
 
interval. Viable HIV was isolated from the blood sample on 17th day of 
autopsy, pleural fluid on 14th day of autopsy, and pericardial fluid on 16th 
day of autopsy. He concluded that there is no time period when autopsy 
can be performed without risk of infection to HIV. Therefore delay in 
performing postmortem will not abolish the risk of HIV infection. 
Henrikki Brummer et al (1994)35 studied the stability of 
antibodies to HIV from serum samples and bilious fluid collected from 8 
HIV-positive postmortem cases. The postmortem interval of the autopsy 
was on an average of 5 days. Serum and bilious fluid samples were stored 
at 27°C for 50 to 310 days for testing. Detecting antibodies to HIV in 
postmortem samples depends on the stability of the antibodies and 
sensitivity of the screening tests. He concluded that HIV antibodies can 
be detected for weeks to months in postmortem specimens, even if stored 
at room temperature. Postmortem testing for antibodies to HIV in 
autopsies thus appears to be a reliable for monitoring the prevalence of 
asymptomatic carriers in autopsy series and screening for safety purposes. 
Zehner et al (1995)36 conducted the study to detect HIV antibodies 
in postmortem blood samples. Before commencing the autopsy, totally 
456 samples were collected and was tested using the HIV 1/HIV 2 Test 
pack. The samples showing positive result for HIV were confirmed by 
Western blot. Among the study sample, 21 cases were proved to be 
 
 
 
positive and it was confirmed by Western blot. The study concludes that 
this HIV-Test pack gives proper results to HIV antibodies in whole blood. 
Cattaneo et al (1999)37 studied the Prevalence of antibodies to 
HIV   among the blood samples from the medico legal cases. This study 
was conducted in 397 individuals aged between 16 to 50 years. These 
cases were tested for HCV and HIV antibodies. Out of 134 individuals 
who were tested positive overall, 20 individuals were found positive for 
HIV antibodies alone, 69 individuals were found positive for HCV 
antibodies alone, and 45 individuals were found positive for both HIV 
and HCV antibodies. Cattaneo et al concluded that significant population 
had risk of dangerous infection in medico legal autopsies. 
Tjotta et al38 demonstrated that HIV survived   in dried blood at 
room temperature for up to five or six days if the optimum pH level is 
maintained. The HIV infectivity in the blood does not appear to be 
affected by drying. 
Hossein Sanaei-Zadeh (2002)39 studied the seroprevalence of 
HBV, HCV and HIV in autopsies, at Tehran. Postmortem blood samples 
were collected in 173 cases for a period of 1 year, out of which 8 were 
positive for Hbs Ag, and 7 cases were also positive for Hbs Ag and anti-
HCV. No case was positive for anti-HIV 1 and HIV 2. He concluded that 
all medico legal autopsy cases, including cases that were thought to be at 
 
 
 
low risk, must be considered as highly and dangerously infectious. 
Therefore suitable precaution must be carried out during necropsies. 
Kaplan JC, Allan JD, Groopman JE et al40 isolated the viable 
HIV from cranial bone, cerebrospinal fluid and brain up to five days after 
death. 
Nyberg et al41 Studied the viability of  HIV in post mortem 
samples and concluded that HIV-infected patients should apparently be 
considered potentially infectious for at least one or two weeks 
postmortem. HIV was cultured from tissue specimens at autopsy up to 6 
days post mortem and from spleen specimens stored for 14 days. He 
suggested precautions, including for bone, during autopsy of HIV-
infected patients even after extended postmortem intervals. 
Johnson et al42 documented occupational transmission of HIV to a 
forensic pathologist in the US who sustained injury with scalpel. 
Eriksen MB et al (2009)43 reported the Postmortem Detection of 
HBV, HCV and HIV genomes in the blood samples among deaths in drug 
addicts in Denmark with rapid kits. He collected the blood samples from 
autopsy cases and screened for HIV antibodies and hepatitis antibodies. 
The screening of viral genome was performed by polymerase chain 
reaction (PCR) technique. HIV genome was detected positive in about 
 
 
 
40% of samples. Hepatitis B virus genome was detected in about 20% of 
anti-HBc – positive/anti-HBs-negative samples. 
Sonia Mehta et al (2012)8 conducted Pre-testing Screening for 
HIV antibodies before Conducting Post-mortem. A total of 328 samples 
of blood were collected prior to the autopsy and tested for antibodies to 
HIV for a period of three years. The study was routine confidential and 
anonymous testing for HIV antibody. Only 2 samples (0.6%) were found 
to be HIV reactive,   average postmortem interval was about 24 hours. 
None of the cases had a known HIV status. This study   concluded that 
universal precautions as suggested in autopsy cases not practically 
possible in a developing country like ours, therefore such pretesting may 
be necessary. 
 
 
 
 
 
HISTORY AND DISCOVERY OF AIDS 
DISCOVERY OF HIV: 
AIDS was first recognized in the year 198144, with reports of a 
sudden unexplained outbreak of two very rare diseases, Pneumocystis 
cariini pneumonia (PCP), and Kaposi sarcoma (KS). It is usually seen 
among   drug addicts and homosexuals. They lost their immunity and 
becoming more prone to many opportunistic infections and other 
secondary neoplasms. Many cases of PCP and KS emerged in the year 
1981 and it alerts the CDC and this made the CDC to observe the 
outbreak45. 
Initially, the CDC has not coined official name for AIDS. It was in 
the year 1981, the term GRID was used by the general press, which 
stands for gay related immune deficiency 46. Later the CDC had coined 
the name as "the 4H disease" as it mean for Haitans, 
Homosexuals, Haemophiliacs and Heroin users47. Later it was determined 
that AIDS was not only related to the gay community alone. It was 
recognized that the name GRID was deceptive, therefore the 
name AIDS in the year 1982. Then CDC uses the name Acquired 
immune deficiency syndrome.48 
 
 
 
In 1983, Robert Gallo in United States and the French scientist Luc 
Montagnier from the Pasteur Institute of Paris independently stated that a 
retrovirus is the cause of AIDS. Gallo claimed that a virus isolated from 
an AIDS patient was similar to other (HTLVs). Robert Gallo gave the 
name for this newly isolated virus as HTLV-III49. 
Montagnier's et al isolated a virus from a individual presenting 
with, classic symptoms of AIDS. Montagnier revealed that core proteins 
of the isolated virus were immunologically different from those of 
HTLV-I and named that isolated virus as lymphadenopathy-associated 
virus (LAV)45. During the commencement of 20th century HIV appeared 
first in humans in Africa as a result of SIV infection. 
Serological tests were available for the anti-HIV antibodies 
detection. The estimation of the extent of HIV infection is made more 
realistic only after the serological tests available. The generic name 
human deficiency virus (HIV) 3 was finalized in 1986 by international 
committee on Virus Nomenclature. 
HIV-1 and HIV-2 are the result of several cross-species 
transmissions of simian immunodeficiency viruses (SIVs) naturally 
infecting African primates.  Both HIV-1 and HIV-2 seemed to have 
originated in non-human primates in West-central Africa and by a process 
 
 
 
known as zoonosis; it was transferred to humans in the early 20th 
century50. 
The origin of HIV-1 is through the evolution of SIV, a simian 
immunodeficiency virus in southern cameroon that infects chimpanzees51, 
52.  SIV is the closest relative of HIV-2, a virus of the sooty mangabey 
residing in West Africa53. HIV-1 is believed to have skipped the species 
barrier on three distinct occasions, giving rise to the three groups of the 
virus namely, M, N, and O53. 
It is believed that human beings who take part in chopping meat of 
monkeys, either as vendors or hunters, usually get SIV54. Simian 
immunodeficiency virus needs several transmissions from one person to 
another person in rapid succession to give sufficient time for mutation to 
HIV55. 
The earliest well recognized case of HIV in human being dates 
back to 1959 in the Congo56. It have been existing in the United States as 
early in 196657, but   the infections outside the Africa can be found back 
to a single  person who got infected with HIV in Haiti and then 
transported the infection to the United States around57. 
Among HIV-1 and HIV-2, HIV-1 is closely related to virus that 
was isolated from species of chimpanzees and gorillas. The chimpanzee 
 
 
 
sub-species Pantroglodytes have been established to be the natural 
reservoir of the HIV-1 M (Major) and N (New) groups. The HIV-1 O 
(Outlier) group is related to the viruses that originate in Cameroonian 
gorillas58. 
The M group consists of nine subtypes, named as A, B, C, D, F, G, 
H, J, and K and circulating recombinant forms (CRFs) 59. By infection of 
an individual with two different subtypes to create a new virus with a 
selective advantage is known as circulating recombinant forms CRFs . 
 
 
 
 
 
 
 
 
 
 
 
 
 
STRUCTURE OF HIV: 
HIV belongs to a retrovirus class of viruses. Within this class, it 
comes under the subgroup called lentivirus. Some other lentiviruses 
include Simian Immunodeficiency Virus (SIV), Feline Immunodeficiency 
Virus (FIV), Visna and (CAEV) Caprine Arthritis Encephalitis Virus. 
Mostly viruses store their genome as long strands of DNA but 
Retroviruses are composed of RNA. HIV is an enveloped, spherical, 
icosohedral virus about 90-120 nm in size. The outer envelope consists of 
lipid bilayer with regularly arranged spikes or knobs which are 72 in 
number. The outer envelope of HIV-1 has gp120/gp140, whereas the 
outer envelope of HIV2 has gp41/gp36.Both are responsible for HIV 
infection. 
The virus core contains 
(1) capsid protein p24; 
(2) nucleocapsid protein p7 / p9-Regulation of gene expression 
(3) 2 copies of genomic RNA; and 
(4) 3 enzymes (protease, reverse transcriptase, and integrase) for 
viral replication and maturation. 
The viral antigen p24 is used for the diagnosis of HIV infection in 
the Enzyme-linked immunosorbent assay (ELISA). The outer core of the 
 
 
 
viral is bounded by a matrix protein called p17, which lies underneath the 
envelope. 
 
The diploid genome composed of 2 identical single-stranded, 
positive sense RNA copies. When the virus infect the cell ,viral RNA is 
transcribed by the enzyme reverse transcriptase , into single stranded 
DNA and then to double stranded DNA (Pro virus) which is integrated 
into the host cell. This provirus remains latent for long period and in 
response to viral promoters it commences the viral replication by the 
synthesis of viral RNA. 
The HIV-1 RNA genome contains the gag, pol, and env genes, 
which are typical for retroviruses. The gag and pol genes products are 
 
 
 
translated primarily into large precursor proteins and then cleaved by the 
viral enzyme protease to produce the fully matured proteins. HIV 
comprises numerous accessory genes such as vif, nef, tat, rev, vpr, and 
vpu, which control the synthesis and assembly of infectious viral particles 
and its pathogenicity. 
TYPES: 
HIV is a highly inconsistent virus which readily mutates according 
to the necessity. There are different strains of HIV in different individuals 
and many strains of HIV can be seen within the body of the same 
individual. HIV can be classified in to two types genetically and 
antigenically. On the basis of genetic similarity, HIV strains can be 
classified further into groups and subtypes. 
HIV-1 is worldwide predominant while HIV-2 is found mainly in 
West Africa but rarely elsewhere. Both types are transmitted in the same 
way, and they cause clinically indistinguishable AIDS.  The transmission 
of HIV-2 is less compared to HIV-1, and the incubation period which is 
between the time of infection to appearance of symptoms of illness for 
HIV-2 is longer. HIV-2 is closely linked to the SIV found in West Africa. 
 
 
 
 
 
SUB-GROUPS AND SUB-TYPES: 
The HIV-1 strains can be categorized into four Subgroups: the 
major group M, the outlier group O and two new groups, N the new and 
another strain P. The strain P was found in 2009 closely linked to gorilla 
simian immunodeficiency virus. 
Group M constitutes greater than 90 percent of HIV-1 infections 
and are responsible for world pandemic. In group M there are nine 
genetically distinct subtypes. Based on nucleotide sequence analyses of 
the env and gag genes, within the M group of HIV-1 there are also at least 
10 different subtypes they are designated from A to K. 60 
Type C is the predominant form not only in India but caused the 
most infections worldwide. The Subtype B is most prevalent in the 
Americas and Europe, but globally subtypes C accounts for half of all 
strains62. The reason for high prevalence of subtype C is due to the 
predominance of it in Africa and India. Subtype D is more virulent due to 
its effective binding to immune cells61. The Type O HIV-1 is often found 
in Cameroon and Gabon and the rare sub-group N is also found in 
Cameroon. 
HIV-2 infection differs from HIV-1 in being inherently resistant to 
non-nucleoside reverse transcriptase inhibitors (NNRTIs) and patients 
 
 
 
have low viral load, lower rates of vertical transmission, slower decline in 
CD4 count and several fold slower progression to AIDS. Rarely, many 
subtypes can meet in the cell of an infected person and combine their 
genetic material to generate a "circulating recombinant forms" or CRFs is 
a mixture of different subtypes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MODES OF TRANSMISSION: 
HIV infection is a communicable disease and can be transmitted 
from person to person, most commonly by having unprotected sexual 
intercourse.  HIV is present in blood, semen and other body fluids such as 
breast milk, urine, saliva, sweat, tears, pre-ejaculated fluid and vaginal 
fluid and can be transmitted by various methods. Worldwide, 
heterosexual transmission being the major route (>75%) and vertical 
transmission (5-10%)63. 
SEXUAL CONTACT: 
HIV is a sexually transmitted disease (STD) and it seems to be 
transmitted from female to male with greater effectiveness than from 
male to female. It can be transmitted through unprotected sexual act from 
an infected individual. The risk of becoming infected with an act of 
unprotected sexual practice depends on the amount of virus in the body 
fluids, the presence of other sexually transmitted diseases. 
VERTICAL TRANSMISSION: 
HIV positive women can transmit HIV to her child either during 
pregnancy or during the process of delivery or by the route of mother’s 
milk. The HIV infected pregnant woman can transmit to fetus or newborn 
a rate varies from 15-40%. This rate can be reduced to levels below 5% 
 
 
 
with effective interventions. HIV is thought to be transmitted during the 
last weeks of pregnancy or during delivery63. 
OCCUPATIONAL EXPOSURE: 
An occupational exposure may place a worker at risk of HIV 
infection through injuries such as those involving a potentially 
contaminated needle or sharp instrument or chapped, abraded skin or 
contact with mucous membranes. The risks for occupational transmission 
of HIV differ with the type and severity of exposure. Seroconversion is 
defined as a situation in which seronegative health care worker  sustains 
an injury with a device soiled with blood or body fluids from a HIV 
seropositive or unknown source and seroconverts within the succeeding 6 
months. 
The average risk for HIV transmission after percutaneous exposure 
to HIV-infected blood has been expected to be about 0.23%64. Average 
risk after a mucous membrane exposure is estimated to be approximately 
0.09% Factors associated with an increased risk of transmission 
comprises: deep injury, injury produced by a device that penetrates a 
blood vessel, hollow-bore needle injury, and a source with high viral 
load8. 
 
 
 
 
NEEDLE SHARING: 
Injectable-drug users share the same needles where the blood 
contaminated needle of one person come into direct contact with other 
individual. Sharing contaminated needles with individuals infected by 
HIV will infect the new individual, due to the direct contact of blood of 
infected individual.  Accidental needle prick injuries are common in 
health care workers but the risk of HIV transmission through needle prick 
injury is less than 1 percent. 
DIFFERENCES IN TRANSMISSION AMONG SUBTYPES: 
Specific subtypes or CRFs of HIV are specifically related to 
specific mode of transmission1. The Subtype C and CRF A/E are spread 
mostly by heterosexual contact, while subtype B is spread mostly by 
homosexual contact and drug addiction. 
Percentage of risk in different modes: 
• Sexually – about 0.5% 
• Parenterally – about 90% 
• Vertical transmission – 15-40 % 
• Drug addiction - 0.5-1.0% 
• Occupational transmission - 0.2% 
 
 
 
 
PATHOPHYSIOLOGY OF HIV: 
After the entry of virus inside the human body there is a 
rapid replication of virus resulting in a great quantity of virus in the 
peripheral blood. There are several million virus particles per milliliter of 
blood during primary infection. It is accompanied by reduction in the 
circulating CD4+ T cells. This is followed by the activation of CD8 T 
cells, which kill HIV-infected cells, and subsequently produces the 
antibody, known as sero conversion period. When the CD8+ T cell 
response is good, the disease progression is slowed down and a better 
prognosis is obtained. 
  HIV causes AIDS by depleting CD4+ T helper lymphocytes which 
weakens the defense mechanism and makes the individual susceptible to 
opportunistic infection. 
In the acute phase HIV induces lysis of cells and killing of infected 
cells by activation of cytotoxic T cells occurs which accounts for 
depletion of CD4 T cell. In the chronic phase, the generalized activation 
of defense mechanism with the gradual loss of the capacity of the body to 
generate new T cells results in slow decline in CD4+ T cell numbers. 
The characteristic symptoms of AIDS does not appear for many 
years after a person is infected, the loss of CD4+ T cell occurs during the 
 
 
 
first few weeks of infection, particularly in the mucosa of the intestine, 
which harbors most of lymphocytes present in body. HIV lodges and 
abolishes CCR5 expressing CD4+ T cells during acute infection.  
NATURAL HISTORY OF HIV/AIDS: 
HIV infection has 4 stages: 
1) Primary infection  
2) Early immune deficiency 
3) Intermediate immune deficiency 
4) Advance immune deficiency 
1) Primary infection 
 There is a fast proliferation of the virus in the lymph nodes and 
blood following HIV infection. In this stage there is a sero conversion 
illness which resolves within weeks. There is a rapid declination of the 
CD4 count before the virus is controlled by the immune system.  
 2) Early immune deficiency 
 In this stage, the immune system has controlled the virus 
particularly the lymphoid tissue and people who are infected with HIV 
are usually asymptomatic. 
 
 
 
3) Intermediate immune deficiency 
 There is a rapid replication of virus and CD4cell turn over and 
CD4 cell count will be around 200-500 count/microlitre, Signs and 
symptoms begin to appear in this stage. 
4) Advance immune deficiency 
 The virus proliferates all over the body and overcomes the defense 
system. Oppurtunistic infections and chance of malignancies are common 
in this stage. 
 
  
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES OF HIV INFECTION: 
The WHO system uses the following classifications: 
STAGE 1 : Primary infection, 
STAGE 2 : Clinically asymptomatic stage, 
STAGE 3: AIDS-related complex or persistent generalized 
lymphadenopathy, 
STAGE 4 : AIDS. 
STAGE 1: Primary HIV infection 
This primary HIV infection lasts for a few weeks and is frequently 
accompanied by a flu-like illness for a short period.  This is seen in 10% 
of individuals and matches with seroconversion. They present with 
mononucleosis like illness which includes sore throat, fever, lymph node 
enlargement, joint pain, skin rash, and malaise. 
In this stage, the defense mechanism of the body responds to the 
virus by producing antibodies to HIV a process called seroconversion. 
Large amount of virus will be present in the peripheral blood in this 
primary stage. 
 
 
 
 
STAGE 2: Clinically asymptomatic stage 
As the name indicates, this stage is without major symptoms, and it 
lasts approximately for ten years. In the peripheral blood, the HIV falls to 
low levels but still the people remain infectious. Antibodies to HIV may 
be detected in blood, showing positive result. Children will have a shorter 
incubation period. Only lymph node enlargement may be present in this 
stage. 
STAGE 3: AIDS-related complex 
In this stage the immune system becomes impaired severely. This 
is due to: 
¾ Impairment of the lymph nodes. 
¾ HIV mutation, leading to T helper cell impairment. 
¾ Failure to replace T helper cells that are lost. 
This stage is usually characterized by multi-system disorder which 
comprises of immunology, dermatology, hematology and nervous system. 
Constitutional symptoms, such as weight loss, fever and night sweats, 
may develop. Generalized lymph node enlargement may be present. 
 
 
 
 
STAGE 4:  AIDS 
The period of clinical latency differs in time from 1 to 2 years to 
more than 15 years .The transition from stage 3 to full-blown AIDS may 
happen quickly or slowly. The progression of the disease is predisposed 
by stress, cofactors, and genetic factors. The poor prognostic factors 
include decrease in the CD4 lymphocyte count and the reappearance of 
HIV antigen in the blood. The individual may develop gradually severe 
opportunistic infections as the immune system becomes severely 
damaged, leading eventually to a full blown disease. In this stage, 
opportunistic infections such as protozoa, fungi, bacterial and viral 
diseases are seen in patients with AIDS.68 
OPPORTUNISTIC INFECTIONS 
PROTOZOAL 
Toxoplasmosis 
Pneumocystis Carinii  
Cryptosporidiosis  
BACTERIAL 
Mycobacterium avium complex  
Atypical mycobacterial disease  
Extra-pulmonary TB  
 
 
 
Salmonella septicemia  
Multiple or recurrent pyogenic bacterial infection 
FUNGAL 
Candidiasis 
Crytococcosis 
Histoplasmosis 
Coccidiodomycosis 
VIRAL 
Cytomegalovirus  
Herpes Simplex Virus  
Varicella Zoster Virus  
Opportunistic infection is caused by bacteria, protozoa, fungi, and 
viruses in patients with AIDS. Pneumocystis carinii causes pneumonia is 
the most common opportunistic infection in patient with AIDS. The 
classic symptoms are breathlessness, cough and fever. Diagnosis includes 
bronchoscopy and the detection of Pneumocystis in the lavage. 
Pentamidine and co-trimoxazole are the treatment of choice. 
 
 
 
Toxoplasmosis is dangerous because it affects brain. The treatment 
is a pyrimethamine and sulfonamide combination. Cryptosporidium often 
causes persistent diarrhea. 
The second most common opportunistic infection in a patient with 
AIDS is candida albicans. Oesophageal candidiasis is most commonly 
seen in patients with pre-AIDS. Treatment is with amphotericin or 
ketaconazole.   Cryptococcus neoformans infection is fatal, if untreated. 
Diagnosis may be made earlier by the demonstration of the fungal antigen 
or fungus in the cerebrospinal fluid. 
The commonest viral infections during HIV are caused by Herpes 
Simplex Virus, Cytomegalovirus, Varicella Zoster Virus. CMV causes 
retinitis and pneumonitis. HSV and VZV infections can be treated by 
acyclovir. 
OPPORTUNISTIC TUMOURS 
The common tumour is Kaposi's sarcoma which is vascular in 
nature is seen in 20% of patients with AIDS. In an average, 35% of 
patients have diseases of the mucosal membrane of the oral cavity, 
larynx, and most commonly the oesophagus, stomach and the intestines 
are affected. Excision and local management with vincristine are the 
palliative treatment. 
 
 
 
Lymphomas of the HIV-infected individuals differ from other 
known lymphoma individuals by their site, degree of malignancy, and 
response to therapy. HIV-associated lymphomas are often found outside 
the lymphatic system, mostly in the brain, GI tract, bone marrow, and 
skin. Their response to treatment is less compared to that of classical 
lymphomas. 
NEUROLOGICAL MANIFESTATIONS  
Neurological changes present in HIV-infected patients ranges from 
mild neuropsychological symptoms such as memory loss, mood 
disturbances and behavior abnormalities to organic psychosis and 
dementia. The most common neurological disorder is subacute 
encephalitis (AIDS dementia complex and AIDS encephalopathy) which 
is present in 33% of cases. Other manifestations are peripheral 
neuropathy, aseptic meningitis, and acute meningoencephalitis. 
DERMATOLOGICAL MANIFESTATIONS 
Skin manifestations are seen in all stages of HIV infection which 
can be the first manifestation which makes the patient to give medical 
attention. Oral hairy leukoplakia, Seborrhoeic eczema and pruritis with 
maculopapular eruption are frequently observed in AIDS. Acne and 
allergic skin eruptions are also common. Skin eruptions such as 
 
 
 
molluscum contagiosum, herpes zoster, condylomata acuminatum are 
also frequently present. 
GASTROINTESTINAL MANIFESTATIONS 
Persistent diarrhoea which is profuse is a recurrent problem in 
AIDS patients. Shigella, Salmonella, Giardia lamblia, Entamoeba 
histolytica, and Campylobacter are responsible for the persistent diarrhea. 
Other organisms such as Cryptosporadium, Mycobacterium avium or 
Karposi's sarcoma may also present with persistent diarrhea in patients 
with AIDS. 
 
 
 
 
 
 
 
 
 
 
 
COURSE OF HIV INFECTION: 
Typical progressors 
Rapid progressors 
Longterm – nonprogressors (LTNP s) 
Typical progressors : 
Typical progressors constitute an average of 85% of HIV infected 
individuals with a survival time of about 10 years. It has three phase’s 
namely primary infection, clinical latency and clinically apparent disease. 
Progression of HIV to full blown AIDS occurs in period of 8-10 years 
approximately. 
Rapid progressors: 
Rapid progressors constitute about 10% of HIV infected 
individuals with a median survival time of about 3-4 years after 
seroconversion. Progression of HIV is rapid in these individuals because 
of defective immune response and CD8 cell mediated suppression. 
Longterm-nonprogressors(LTNP s): 
About 5% of the HIV infected individuals are called Longterm –
non progressors (LTNPs). These individuals have stable CD4 cell count 
without any therapy for a long period. The CD4 count in these individuals 
 
 
 
is usually more than 500. They have a high titre of neutralizing antibodies 
to HIV. Cell mediated immune response and humoral mediated immune 
responses are high in these persons. Viral load and replication of virus is 
four fold higher in these individuals in the lymph node and blood.61 
REPLICATION CYCLE OF HIV: 
The HIV life cycle includes the series of events that starts from the 
attachment of virus to the CD4 receptors on the host cell surface, and 
ends with the release of new viruses that bud off from the new host cell. 
HIV can infect several cells in our body, but its target is the CD4 
lymphocyte. When a CD4 lymphocytic cell is infected with HIV, it 
undergoes many steps to replicate and generate many new viruses. 
The replication of HIV can occur inside the human cells only. The 
replication process begins when a virus particle enter into a cell that 
carries on its surface a special protein called CD4. The virus particle 
contains spikes on its surface which stick to the CD4 and permit the viral 
envelope to fuse with the cell membrane. The HIV genomic particle then 
gets released into the cell, and leaves the envelope on the surface of the 
cell.66 
 
 
 
 
 
Binding and Fusion:  
The surface membrane of living cells consists of complex protein 
structures called receptors.  The HIV life cycle begins when the HIV 
binds to the CD4 receptor and its co-receptors on the membrane surface 
of a CD4 T-lymphocyte. Then it fuses with the host cell, thereby 
releasing RNA   into the host cell. The firm attachment of the viral 
particle to the CD4 receptor helps in fusion of HIV with the cell 
membrane and release of its genome into the host cell. 
Reverse Transcription:  
The enzyme called reverse transcriptase which reads the sequence 
of viral RNA nucleic acid and converts the single – stranded HIV RNA to 
double-stranded HIV DNA. 
Integration: 
After the reverse transcription of viral RNA, the HIV DNA enters 
the nucleus of the host cell; the enzyme integrase hides the HIV DNA. 
The integrated HIV DNA is called provirus which becomes inactive for 
many years, making copies of HIV66. 
Transcription: 
 
 
 
The transcription occurs only when the lymphocyte is activated. 
After receiving a signal, the provirus utilizes the host enzyme RNA 
polymerase, to make copies of the HIV RNA, and also shorter strands of 
RNA named messenger RNA. The mRNA acts as a blueprint to create 
long chains of HIV proteins. 
Assembly: 
The Protease enzyme splits up the long chain of HIV proteins into 
small proteins. When the smaller HIV proteins and the HIV genomic 
material come together, a new virus particle is formed. 
Budding: 
The virus which is formed newly will be pushed out of the host cell 
which is called as budding. The new formed virus takes a portion of the 
cell's outer envelope which is covered with protein and sugar 
combinations called HIV glycoproteins. These glycoproteins are essential 
for the virus to bind CD4 and co receptors. The new HIV copies can 
infect other cells. 
HIV replication is related with a high mutation rate because reverse 
transcription does not permit for rectification of errors in nucleotide 
incorporation. HIV evolves million times faster than the human genome 
 
 
 
evolution thereby making tough for the immune system to identify and 
efficiently combat.67 
LABORATORY DIAGNOSIS OF HIV: 
HIV diagnostic testing has become available for the detection of 
antibodies to HIV only in the 1980s. To detect antibody as early as 
possible after infection, the enzyme immunoassays are sensitive. To 
confirm positive antibody screens, a variety of other assays are available. 
Purpose of HIV testing69 
• For prophylaxis and management. 
• For blood safety and donation safety. 
• For monitoring the epidemic (sentinel surveillance) 
• Identification of asymptomatic individuals. 
• To encourage for behavior modification through counselling. 
• To diagnose clinically suspected cases. 
• Voluntary testing after counseling 
SEROLOGICAL TEST INCLUDES: 
a) Antibody tests 
b) Antigen tests 
 
 
 
(a) Antibody tests: 
For screening of blood samples for antibody to HIV Enzyme 
Linked Immunosorbent Assay (ELISA) is the most commonly performed 
method. The sensitivity and specificity of the present systems reaches 
100% but false positive and false negative results cannot be excluded. 
Other antibody tests are Western blots, immunofluorescence, passive 
particle agglutination, and RIPA bioassays. Western blots are considered 
as the gold standard and seropositivity is diagnosed when antibodies 
against both the env and the gag proteins are detected69. 
(b) Antigen tests: 
Before the appearance of antibody to HIV; antigen can be detected 
early in the course of HIV infection. Antigen is not detectable during the 
latent period of HIV infection but become it becomes detectable during 
the last stages of the infection. 
Demonstration of viral nucleic acid: 
This can be accomplished by probes or by PCR techniques. The 
Polymerase chain reaction may be exceptionally useful because of its 
extremely high sensitivity. 
 
 
 
 
Methods to detect specific HIV antibodies: 
i. Screening tests 
ii. Supplemental tests 
SCREENING TESTS: 
The Enzyme-Linked Immunosorbent Assay (ELISA) usually takes 
2-3 hours to yield the results. Rapid screening tests give results within 
minutes and include visual assays like dot blot tests, particles (gelatin, 
RBC, latex, micro beads) agglutination, HIV spot and comb test and 
fluorometric micro particle technologies. These tests are easy to perform, 
rapid, do not require sophisticated equipment, technical expertise and are 
mostly cost-effective. They also distinguish HIV-1 and HIV-2 
antibodies.70 
ELISA 
The Enzyme-Linked Immunosorbent Assay is the most commonly 
performed screening test which is easy to carry out for a large sample 
size. It is highly sensitive, specific and cost-effective. The Enzyme-
Linked Immunosorbent Assay is a technique used to detect the presence 
of an antigen/antibody in a specimen sample. It utilizes two antibodies, 
one is specific to the antigen and the other is coupled to an enzyme. The 
second antibody produces a fluorogenic or chromogenic substrate to 
 
 
 
produce a signal. It is a device for determining serum antibody as well as 
the antigen. ELISA based on indirect method is used in most of the kits.70 
SUPPLEMENTAL TESTS: 
The samples which are reactive in the screening tests were 
confirmed with the help of supplemental tests for the confirmation of 
diagnosis.  
When the sample is reactive by any one of the screening tests, it is 
tested by another different system to confirm the diagnosis. If a specimen 
is reactive in 2 different systems, it has to be tested again using one of the 
supplemental tests which may be a third ELISA Enzyme-Linked 
Immunosorbent Assay or Rapid test or a Western Blot test (WB). 
WESTERN BLOT  
For detecting HIV antibodies, the Western blot is the most 
commonly performing confirmatory assay. It is considered as the gold 
standard for confirmation of HIV infection. This technique is based on 
electrophoresis which denatures the proteins of the viral components and 
imparts negative charge to the antigens, and separates the antigens on the 
basis of their molecular weight. The separation of antigens permits the 
identification of specific antibodies to the viral antigens. 
 
 
 
RAPID ASSAYS: 
¾ Particle agglutination 
¾ Dotblot assays 
¾ Immunochromatography 
¾ HIV spot and comb tests 
¾ Dipstick and comb assays 
There are many rapid assays which work on the principle of 
agglutination and Enzyme-Linked Immunosorbent Assay has been 
developed for quick results and easy performance. These rapid assays 
usually require 30 minutes or lesser time for performing the test and does 
not require any special equipment’s.70 
DOT BLOT ASSAYS 
This rapid assay is easy to perform, and it can generally distinguish 
between HIV-1 and HIV-2 and do not require complicated equipments. 
The results are indicated by development of color. One of the drawbacks 
of the test is the high cost. Sensitivity and specificity of these assays are 
comparable with ELISA. These assays are beneficial for single test 
application (e.g: autopsy room and blood banks, emergency). 
The immune chromatographic assays are 1-step rapid assay test kit, 
which has tools for screening, consisting of a flat cartridge device, plastic 
 
 
 
or paper. Blood, serum or other body fluid is placed at the tip of the 
device and are allowed to diffuse along a strip that is impregnated with 
chemicals mostly colloidal gold that bind and permit visual detection of 
HIV antibodies some use third-generation. These tests can be completed 
in less than 10 minutes and even less than two minutes, no need for 
addition of reagents, and has control reagent to reduce technical errors. 
These can be stored at a different temperature and are transported simply 
without any consequences. 
Based on type of HIV antigen, various types of HIV kits are 
available. First generation kits utilises antigens derived from viruses 
grown in human lymphocytes. Second generation kits utilise artificially 
derived recombinant antigens from   fungi or bacteria. Third generation 
kits use chemically manufactured oligopeptides.  
Laboratory diagnosis during window period: 
Window period is a period of seronegativity during which an 
infected person do not give a positive result to either Western blot or the 
Enzyme-Linked Immunosorbent Assay, even though the viral load is 
high. These individuals may show certain symptoms and this period can 
last for 6 months before seroconversion. . 
 
 
 
During window period HIV infection can be detected by viral 
demonstration and viral components by: 
• Polymerase Chain Reaction 
• p 24 antigen test 
• Culture of virus69 
• Nucleic acid amplification test (NAT) which detects viral nucleic 
acid. 
Other laboratory findings for HIV infection may include 
leukopenia, anaemia and thrombocytopenia. Increased ESR, increased 
blood gammaglobulin, and decreased blood cholesterol level. Post 
exposure testing is suggested at six weeks, three months, and then after 
six months. 
The important target of HIV replication is CD4 cell which results 
in depletion of CD4 cells. Therefore CD4 cell count is a marker for 
staging the HIV infection and monitoring the disease progression .The 
rate of HIV replication is also reflected by increase in plasma viral RNA 
load and is considered as one of the most specific and sensitive test to 
monitor the HIV progression 
 
 
 
 
 
VIRAL LOAD TEST: 
Viral load test is defined as the number of copies of HIV in 1ml of 
blood specimen. The viral load tests determines the amount of HIV RNA 
in a small quantity of blood .The viral load test is valuable for managing 
therapy response, evaluation of newly diagnosed HIV infection, 
surveillance of patients not receiving drug therapy. It will help to predict 
how long the patient will stay healthy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT 
There is no cure for AIDS. The target of antiretroviral treatment is 
to bring the viral load in the body to a low level by suppressing the 
replication of the HIV virus in the body. This helps to reduce the 
weakening of the immune system and allows it to recover from damage 
that HIV might have caused previously. Combination of three or more 
than three anti-HIV drugs is referred to as Highly Active Antiretroviral 
Therapy (HAART). The most common drug combination comprises of 
two nucleoside reverse transcriptase inhibitor with either a non-
nucleoside reverse transcriptase inhibitor or a protease inhibitor71. 
Highly Active Antiretroviral Therapy (HAART) has improved life 
expectancy and prognosis in patients with HIV infection. There has been 
80% decrease in mortality after its introduction. Sometimes there may be 
resistant to one combination of Highly Active Antiretroviral Therapy 
(HAART), especially in patients who skip their medications. 
Antiretroviral drugs in general fall into the following groups72: 
• Nucleoside analogues – Inhibits the reverse transcriptase enzyme 
thereby   preventing replication 
• Non-nucleoside analogues – Inhibits reverse transcriptase enzyme. 
 
 
 
• Protease inhibitors – Prevent viral protein processing. 
• Fusion inhibitor – Inhibit the fusion of viral and cellular membranes. 
Lifestyle factors such as exercise, diet, and stopping smoking, and 
recreational drug use are also important in HIV management. 
POST EXPOSURE PROPHYLAXIS OF HIV: 
Post-exposure prophylaxis refers to the management to reduce the 
risk of infection following exposure to blood-borne infectious organisms. 
At present there are only two ways to diminish the risk of developing 
HIV infection following exposure to HIV post-exposure prophylaxis 
(PEP) and interventions to prevent transmission from mother-to-child.74 
Post-exposure prophylaxis (PEP) comprises taking anti-HIV drugs 
as soon as possible following exposure to HIV to decrease the chance of 
becoming HIV positive. The aim of post-exposure prophylaxis (PEP) is 
to decrease or prevent local viral replication prior to spread of infection, 
so that the infection can be abandoned. 
There are two categories of post-exposure prophylaxis (PEP):  
(1) Occupational PEP, (“oPEP”) 
(2) Non-occupational PEP, (“nPEP”) 
 
 
 
Occupational exposure (oPEP) is said to have occurred when a 
person working in a medical setup is exposed to materials which is 
infected with HIV.  nPEP is when a person is exposed to HIV in some 
other situations like (condom breakage, sexual assault, etc.) To be 
effective, PEP must begin within 72 hours of exposure, before the viral 
replication. PEP consists of 2-3 antiretroviral medications and should be 
taken for 28 days. In addition counseling should be provided because of 
the psychosocial issues.74 
POST EXPOSURE PROPHYLAXIS REGIMEN73: 
Basic two drug regimen (For low risk) 
Zidovudine 300 mg + Lamivudine 150 mg  - Twice daily for 4 weeks 
Expanded three drug regimen (For high risk) 
Zidovudine 300 mg + Lamivudine 150 mg  - Twice daily for 4 weeks 
+ Indinavir 800 mg (or another PI)  - Thrice daily for 4 weeks 
LOW RISK: 
¾ When the source of infection is positive for HIV, but asymptomatic 
with low HIV-RNA titre and high CD4 cell count. 
¾ When the exposure is through the mucous membrane, or 
superficial scratch, or through thin and solid needle. 
 
 
 
HIGH RISK: 
¾ When the source is symptomatic AIDS patient with high HIV -
RNA titre or low CD4 count. 
¾ Exposure is through major splash or large area contact of longer 
duration with mucous membrane or abraded skin or through small 
gauge needle, puncture wound which is deep, and patient’s blood 
on the needle. 
UNIVERSAL PRECAUTIONS DURING AUTOPSY83:  
Universal precautions are intended to follow for blood, vaginal 
secretions and semen as well as to peritoneal, pericardial cerebrospinal, 
synovial, pleura fluids, and it is believed that tears, nasal secretions, 
sweat, sputum, urine, faeces and vomitus and amniotic fluids are not 
infectious unless they contain visible blood. 
Only experts and health care professionals who are skilled in 
handling the infected material are allowed to enter in to the postmortem 
examination room. Only these experienced professionals should conduct 
the autopsy examination because it is proved that the risk of accidental 
infection occurs more common in inexperienced persons.  Studies 
reported that laceration occurred in 1 in every 11 autopsies conducted by 
inexperienced persons. Individuals with immune deficiency and persons 
 
 
 
who have open wounds or skin lesions like dermatitis should not involve 
in postmortem examination. 
The postmortem examination room should be sufficient without 
overcrowding and proper ventilation should be provided. Protective 
measures such as gloves, headwear, masks, eyewear, shoes and full-
covered gown should be used by the mortuary staff while conducting the 
postmortem examination. Gloves should be checked for leakage 
frequently for cuts and puncture. Glove perforation occurs commonly, 
double gloving in the dissection room is suggested to reduce the risks of 
cutaneous blood contacts. 
Hand washing is mandatory after handling blood and body fluids 
contamination and also after the removal of gloves. Contamination with 
blood and/or other body fluids must not be moved from gloved hands to 
other surfaces which may subsequently be touched by ungloved hands 
like door handles, telephone receiver, table, chair, etc. No hand-to-hand 
passing of Sharp instruments while performing postmortem examination 
and it should be handled with great care.  Disposable syringes, needles 
and other sharps should be retained in puncture resistant containers for 
their safe disposal. 
 
 
 
 
PREVENTION OF PERINATAL TRANSMISSION OF HIV 
The rate of HIV transmission can be reduced to two-thirds by 
administration of zidovudine to the women during pregnancy, labor, and 
delivery and also to their newborns. Zidovudine treatment is more 
effective when it is administered during labour or administered to the 
infant, if the treatment is begun in less than 48 hours after birth.74 
If zidovudine resistance is suspected, combination antiretroviral 
treatment is recommended.  A regimen of oral zidovudine between 14 
and 34 weeks of gestation (100 mg five times a day), intravenous 
zidovudine during labor, and zidovudine syrup from birth through 6 
weeks of age has been shown to reduce the rate of vertical (mother-to-
newborn) transmission of HIV by up to 23%. 
PREVENTION: 
There is no effective vaccine against HIV. The only way to prevent 
infection   is to avoid certain risk factors, such as sharing needles or 
unprotected sex. 
Primary Prevention 
Factors that determine the prevention of HIV infection: 
• Precautions concerning safe sexual act and safe injection, 
 
 
 
• HIV prophylaxis in perinatal period, 
• Blood products screening, 
• Infection control in medical profession. 
Secondary Prevention 
The disease progression can be significantly reduced with the 
presently available effective treatment. Along the current effective 
treatment, available prophylactic regimens to opportunistic infections 
prevent the infection and improve the survival rate of the HIV patients. 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
The present study was conducted at the Institute of Forensic 
Medicine, Chennai-3. The study sample consists of 486 routine autopsy 
cases at Rajiv Gandhi Government General Hospital. Before getting into 
the study, Ethical clearance was obtained from the Ethical committee. 
Blood samples were collected from a sum of 486 cases autopsied at 
Rajiv Gandhi Government General Hospital. The samples were collected 
via cardiac chamber or femoral vessel at the time of autopsy. The samples 
were tested blindly that the identity of the individual was unknown.  
None of the cases had a previous or known HIV status. The positive 
results were confirmed by another rapid assay test. 
The samples were tested using an enzyme immunoassay using SD 
Bioline HIV1/2 3.0 Rapid test kits to detect the presence of HIV-1 and 
HIV-2 antibodies. The test procedure was performed according to the 
protocols supplied by the manufacturers. Samples yielding reactive 
results were confirmed by Alere DetermineTM HIV 1/2 method which 
detects HIV-1, HIV-2 antibodies. The present study was carried out for a 
period of 1 year on a dead bodies submitted for medicolegal autopsies at 
the institute of Forensic Medicine, Chennai-3. 
 
 
 
The tested samples are anonymous, and it is collected without 
informed consent. Samples are anonymous, if it is impossible under any 
situation for anyone to identify the source of the sample. It is an 
epidemiological testing for the HIV prevalence in a particular population 
with the minimum of participation bias.  
The individual’s data such as demographics, cause of death, 
postmortem interval and positivity for the type of HIV (HIV-1 
and/orHIV-2) are recorded. SD BIOLINE HIV1/2 3.0 Rapid test kit is an 
immunochromatographic test for the detecting antibodies to all isotypes 
(IgM, IgG) specific to HIV-1 and HIV-2 concurrently in human serum, 
plasma or whole blood qualitatively. 
SD BIOLINE HIV1/2 3.0 SPECIFICATIONS: 
The SD BIOLINE HIV1/2 3.0 Rapid test has a membrane strip 
which has two test band regions. Test band 1 has precoated recombinant 
HIV 1 capture antigen (gp24, p41). Test band 2 has precoated 
recombinant HIV2 capture antigen (gp36). The recombinant HIV1/2 
antigen (gp24, p41 and gp36) gold conjugate and the sample move 
chromatograpically to the test region (T) and develop a visible line as the 
antigen – antibody-antigen gold particle complex with a high degree of 
specificity and sensitivity. This test device has a letter of 1 for test Line 1 
 
 
 
(HIV-1), letter 2 for test line 2(HIV-2) and C representing control line 
respectively on the surface. Test lines and control line are not visible 
before applying any sample. The control line is signifies the procedural 
control. Control should appear if test procedure is performed properly. 
PROCEDURE 
After opening the foil pouch the test device is placed on a dry, 
clean, bright, flat surface. With the help of capillary pipette 20µl of blood 
specimen which is taken directly from the cardiac vessel or femoral 
vessel puncture is added into the sample well (It is indicated with the 
letter ‘S’) in the test device, then four drops of assay diluent is added in to 
the sample well .If the test is in progress, the purple colour moves across 
the result window which is in the center of the test device. Interpretation 
of the test results was done within 5-20 minutes. 
INTERPRETATION 
A colour band that appears in the left section of the test device 
signifies that the test is properly working. This band is control line (C). 
Colour bands that appear in the right and middle section of the 
result window are the test lines. The bands are test line 1(1) and test line 2 
(2). 
 
 
 
NEGATIVE RESULT 
The presence of only control line (C) in the test device designates a 
negative result. 
POSITIVE RESULT 
The presence of two lines - control line(C) and test line 1 (1) within 
the test device designates a positive result for HIV 1. The presence of two 
lines as control line(C) and test line 2 (2) within the test device designates 
a positive result for HIV 2. The occurrence of three lines as control 
line(C) and test line 1 (1) and test line 2 (2) within the test device 
designates a positive result for both HIV-1and HIV-2. 
INVALID RESULT 
Absence of control line (C) within the result window specifies an 
invalid result. The instructions are followed incorrectly or the test sample 
may have been deteriorated. Therefore the specimen should be re-tested. 
LIMITATIONS OF THE TEST 
To diagnose AIDS, Immunochromatographic testing alone cannot 
be used even if the antibodies against HIV-1 and/or HIV-2 are present in 
a deceased specimen. At the same time, negative result does not exclude 
 
 
 
the possibility of HIV-1 and/or HIV-2 infection. This is because the 
specimen may contain low levels of antibodies to HIV-1 and /or HIV-2. 
PERFORMANCE CHARECTERISTICS 
Sensitivity – 100%Specificity – 99.8% 
SPECIFICATIONS OF ALERE DETERMINETM HIV 1/2 
The Alere DetermineTM HIV-1/2 is an in vitro, qualitative 
immunoassay which is visually read for the detection of HIV-1 and HIV-
2 antibodies in human serum, whole blood or plasma. 
PRINCIPLES: 
Alere DetermineTM HIV-1/2 is an immunochromatographic test for 
the detection of antibodies to HIV-1 and HIV-2 qualitatively. When a 
sample is added to the sample pad, it migrates through the conjugate pad; 
it mixes with the selenium colloid-antigen conjugate. This migrates 
through the solid phase to the immobilized recombinant antigens and 
synthetic peptides at the window site. 
If HIV-1 and/or HIV-2 antibodies are present in the sample, the 
antibodies bind to the antigen as well as to the antigen-selenium colloid at 
the patient window, forming a red line there. 
 
 
 
If HIV-1 and/or HIV-2 antibodies are absent in the sample, the red 
line will not be formed as the antigen-selenium colloid flows past the 
patient window. A control bar is incorporated in the assay device to 
insure assay validity. 
TEST PROCEDURE 
The protected foil covering the test card was removed. 50 µl of 
sample was applied to the sample pad, followed by a drop of chase buffer 
after 1 minute. The results were read after a minimum interval of 15 min. 
LIMITATIONS OF THE TEST 
1. The Alere DetermineTM HIV-1/2 detects HIV-1 and HIV-2 
antibodies in whole blood, serum, plasma. Other body fluids or 
pooled specimens may not give accurate results. 
2. The intensity of the patient bar does not necessarily correlate to the 
titre of antibody in the specimen. 
3. A negative result will not ignore the possibility of HIV infection. 
False negative result occur if, 
• Low Antibody levels 
• Infection with a variant of the virus 
• Specimen handling conditions which result in loss of HIV 
antibody multivalency. 
 
 
 
4. Whole blood or plasma specimen containing anticoagulants other 
than EDTA may give incorrect results. 
PERFORMANCE CHARECTERISTICS 
Sensitivity   and specificity- 100% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANALYSIS AND RESULTS 
Of the 486 samples tested, HIV antibodies were detected in 4 
samples using SD BIOLINE HIV1/2 3.0 Rapid test kit. The 4 positive 
samples were tested again by another rapid assay Alere DetermineTM, 
which were also positive for HIV-1. Data such as demographics, cause of 
death, postmortem interval and positivity for HIV-1 and or HIV-2 are 
recorded. 
Out of the 4 positive samples, all were positive for HIV 1and none 
were positive for HIV 2, all were male and all the four positive cases 
were not previously known to have HIV-infection. The presence of two 
murder cases in the four HIV positives indicates that HIV positive cases 
are clustered in homicide cases. 
Males occupy predominant number of cases, accounts for about 
85.8 % of study sample, whereas female constitute only 14.2 % of the 
study sample. Among the positive samples all were male, none of the 
samples were positive for female indicating that seroprevalence is higher 
in males (100%). 
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Among 486 cases analyzed, predominant number of cases falls 
under age group between 21 and 40, followed by age group between 41 
and 60.In this study, Out of the four cases two cases were positive in the 
age group 61-80, indicating that highest seroprevalence was in the age 
group 61-80.   
Table 3: Distribution of cause of death among the positive cases of 
the study sample: 
S.no Cause of death 
No. of 
sample 
No. of positive 
cases 
Percentage of 
positive cases 
1. Natural cause 101 1 0.99 
2. 
Road traffic 
accident 215 0 0 
3. 
Train traffic 
accident 62 1 1.61 
4. Hanging 21 0 0 
5. Fall from height 38 0 0 
6. Murder 11 2 18.1 
7. Poisoning 26 0 0 
8. Other causes* 12 0 0 
9. Total 486 4 0.82 
 
* (Snake bite, Drowning, Electrocution, Burns) 
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DISCUSSION 
The HIV estimation in India was first done in 1994 based on data 
from different sites. The People Living with HIV/AIDS (PLHA) in India 
in the year 2007 is estimated to be 2.31 million. Globally there are about 
33.4 million people living with AIDS (PLHA) in the year 2008.  HIV 
prevalence in adults as per the year 2009 estimate was 0.31%, which was 
higher among males than females. 
A simple, reliable, and rapid test to detect HIV infection can be 
useful in the mortuary because it is not possible always to get the 
complete and correct information about all of the risk factors before 
commencing the postmortem, because of the social and cultural 
restrictions. Therefore the lack of a known history of such a risk factor 
does not equate with the nonexistence of such risk factor. Hence testing 
for HIV in medico-legal autopsies will identify carriers in whom HIV 
status was not previously known. 
In countries like Iran, Finland, Germany etc., screening of HIV 
antibodies in autopsy was done as a back-up surveillance programs based 
on voluntary tests75. In the population where refusals are common for 
voluntary HIV tests, screening during postmortem efficiently reveals the 
true incidence of HIV without bias. Among 7305 medico-legal autopsies 
tested from 1986 to 1990 at Finland, nine cases were positive for HIV 
 
 
 
(0.12%). This percentage is greater than the prevalence of 0.01 to 0.03% 
in voluntary screening programs from the general population. In this 
study, the four positive cases out of 486 cases were not known to have 
HIV which means they are clinically undetected for HIV antibodies. This 
indicates that that people at high risk are clustered in the medico-legal 
autopsy series76. 
There are many studies that have estimated the survival of the HIV 
postmortem.  Viable HIV can be isolated from blood at autopsy up to 21 
hours of postmortem interval under situations of proper body storage76. 
Nyberg et al isolated viable HIV up to 14 days postmortem. Karhunen et 
al. suggested from his results that HIV antibodies can be detected in 
biological fluids, if stored for months even at room temperature75. During 
the early phase of infection, the viral load in blood and other body fluids 
may be very high. This suggests the need for efficient protection of 
autopsy personnel’s during all autopsies. 
The testing of postmortem sera for antibodies to HIV will be a 
most reliable and accurate measure of antemortem HIV infection. 
Antibodies to HIV have been shown to remain detectable in postmortem 
serum stored for relatively long periods of time, more than 60 days at 4°C 
and up to 176 days at -70°C without degradation77. Furthermore, it has 
been demonstrated that extensive hemolysis of cadaveric blood does not 
 
 
 
interfere with ELISA or Western blot analysis of HIV seropositivity. In 
general, proteins such as the globulins that comprise antibodies may not 
be affected by postmortem decomposition, hemolysis, or bacterial 
contamination77,18. In this study, it was estimated that the postmortem 
interval was ranging from 8 hours to 26 hours for detection of HIV 
antibodies. 
Postmortem viral level is influenced by several factors like viral 
burden of death, viral strain, pre-mortem antiviral therapy and 
temperature maintained in the mortuary. Blood, vaginal fluid, semen, 
breast milk, and cerebrospinal, amniotic, pericardial and synovial fluids 
are the body fluids responsible for transmitting the HIV. Others such as 
saliva, tears, urine are not implicated in the transmission of HIV except 
they contain adequate blood.19,42  
British clinical laboratories conducted a study between 1970 and 
1989 and established that the highest rate of laboratory- acquired 
infections was in mortuary workers. Weston and Lober have recognized 
that about 8% surgical gloves get punctured during post-mortem and 
nearly one third of that was undetected by the pathologist, thus causing 
the infectious blood to be bathed in any preexisting hand injuries for a 
prolonged period of time.25 
 
 
 
In the present study, the samples were tested blindly, that the 
identity of the individual was unknown. This study includes all types of 
forensic autopsy cases representing the general population. Samples of 
blood were collected from 486 autopsy cases at Rajiv Gandhi 
Government General Hospital. All the samples were tested for antibodies 
to both HIV-1 and HIV-2 using rapid standard ELISA kits which has a 
sensitivity of 100% and specificity of 99.8%. 
Out of 486 cases, there are four positive cases and all the positive 
cases were male. These positive cases were further confirmed with 
another rapid-assay kit for  HIV antibodies which is also simple, rapid 
and no special equipment is required and even whole blood can be used. 
This rapid-assay kit has a very high sensitivity of 100% and specificity of 
100% in trials conducted in Asia and tests both HIV-1 and HIV-2. The 
presence of 4 positive cases among 486 cases, though statistically 
insignificant is higher than many other voluntary screening programs. In 
many voluntary screening programs there are people who abstain from 
testing, which does not affect in this study. Thus, screening in medico 
legal autopsy is a sensitive indicator epidemiologically. 
Many studies conducted for detecting the antibodies to HIV in the 
autopsy population were classified the deceased as “known risk” and “no 
known risk” groups based on the history such as infection, drug 
 
 
 
addiction, and sexual contact but that was not reliable and leads to 
misclassification. So, in this study such data about the risk factors were 
not collected. 
           There are two opinions concerning HIV in autopsies. One school 
of thought maintains that all autopsies should be carried with universal 
precaution which is almost impracticable in a developing country79,80. The 
second thought recommends pre autopsy testing for HIV by rapid test kits 
in the mortuary by taking blood samples from the dead body. If the result 
is positive, then universal precautions to be observed while conducting 
autopsies.8,83 
LIMITATION OF THE STUDY: 
The obstacles for postmortem testing of blood and body fluids 
include hemolysis, autolysis, bacterial contamination, and loss from 
decomposition. These obstacles are enhanced by prolonged postmortem 
intervals. However, immunoglobulins, are considered less likely to be 
affected by decomposition, hemolysis and bacterial contamination79,18. 
This screening test for the antibodies to HIV may not be sensitive 
if someone infected shortly before death and not seroconverted. 
 
 
 
 
CONCLUSION 
The present study concludes that testing of HIV in medico legal 
autopsies is a convenient and effective method in monitoring the 
surveillance of HIV-infection in the general population and it can be used 
for epidemiological studies. It could be used along with unlinked 
anonymous tests from hospital and other similar patient materials. 
Testing for HIV may also be desired for safety reasons in 
mortuaries81. In screening postmortem blood for HIV-antibodies, the 
present study represents that rapid assay test pack is simple, rapid, no 
special equipment are required, even whole blood can be used and has 
very high sensitivity of 100% and specificity of 99.8% and tests both HIV 
1 and HIV 2. 
 Out of 486 subjects in this study group, 4 cases were positive for 
HIV and all were previously unknown seropositive cases. Though the rate 
of infection appears to be less than 1%, even with a needle stick, it is not 
practical or economical to take universal precautions with every autopsy. 
It would, therefore, be advantageous to know a deceased HIV serological 
status prior to autopsy. Screening may be worthwhile in cases at high risk 
of HIV infection where the HIV antibody status is not known at the time 
of postmortem. 
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MASTER CHART 
S.NO P.M.NO SEX AGE 
CAUSE 
OF 
DEATH
HIV-1 HIV-2 CONFIRMATORY TEST 
1 1418/12 M 50 RTA Negative Negative Negative 
2 1419/12 M 40 RTA Negative Negative Negative 
3 1420/12 M 70 RTA Negative Negative Negative 
4 1421/12 F 45 NC Negative Negative Negative 
5 1422/12 M 70 NC Negative Negative Negative 
6 1423/12 M 18 RTA Negative Negative Negative 
7 1424/12 M 38 NC Negative Negative Negative 
8 1425/12 M 45 NC Negative Negative Negative 
9 1426/12 M 38 RTA Negative Negative Negative 
10 1427/12 F 30 RTA Negative Negative Negative 
11 1428/12 M 26 RTA Negative Negative Negative 
12 1429/12 F 53 RTA Negative Negative Negative 
13 1430/12 M 31 RTA Negative Negative Negative 
14 1431/12 M 40 Fall Negative Negative Negative 
15 1432/12 M 27 Hanging Negative Negative Negative 
16 1433/12 M 80 NC Negative Negative Negative 
17 1434/12 M 32 RTA Negative Negative Negative 
18 1435/12 M 55 NC Negative Negative Negative 
19 1436/12 M 63 NC Negative Negative Negative 
20 1437/12 M 24 RTA Negative Negative Negative 
21 1438/12 M 52 Hanging Negative Negative Negative 
22 1439/12 F 83 TTA Negative Negative Negative 
23 1440/12 M 49 NC Negative Negative Negative 
24 1441/12 M 59 RTA Negative Negative Negative 
25 1442/12 M 42 Fall Negative Negative Negative 
26 1443/12 M 78 Drowning Negative Negative Negative 
 
 
 
27 1444/12 M 18 RTA Negative Negative Negative 
28 1445/12 M 35 RTA Negative Negative Negative 
29 1446/12 M 29 Fall Negative Negative Negative 
30 1447/12 M 32 RTA Negative Negative Negative 
31 1448/12 M 42 NC Negative Negative Negative 
32 1449/12 M 86 RTA Negative Negative Negative 
33 1450/12 M 45 NC Negative Negative Negative 
34 1451/12 M 70 NC Negative Negative Negative 
35 1452/12 M 55 NC Negative Negative Negative 
36 1453/12 M 62 Fall Negative Negative Negative 
37 1454/12 M 30 RTA Negative Negative Negative 
38 1455/12 M 60 NC Negative Negative Negative 
39 1456/12 M 35 RTA Negative Negative Negative 
40 1457/12 M 23 RTA Negative Negative Negative 
41 1458/12 M 28 RTA Negative Negative Negative 
42 1459/12 M 62 RTA Negative Negative Negative 
43 1460/12 M 45 RTA Negative Negative Negative 
44 1461/12 M 30 Fall Negative Negative Negative 
45 1462/12 M 25 RTA Negative Negative Negative 
46 1463/12 F 27 Poisoning Negative Negative Negative 
47 1464/12 F 52 RTA Negative Negative Negative 
48 1465/12 M 26 Hanging Negative Negative Negative 
49 1466/12 M 60 RTA Negative Negative Negative 
50 1467/12 M 60 NC Negative Negative Negative 
51 1468/12 M 24 Poisoning Negative Negative Negative 
52 1469/12 M 50 TTA Negative Negative Negative 
53 1470/12 M 32 RTA Negative Negative Negative 
54 1471/12 F 2 Poisoning Negative Negative Negative 
55 1472/12 M 60 NC Negative Negative Negative 
 
 
 
56 1473/12 M 54 RTA Negative Negative Negative 
57 1474/12 M 40 RTA Negative Negative Negative 
58 1475/12 F 38 RTA Negative Negative Negative 
59 1476/12 M 37 RTA Negative Negative Negative 
60 1477/12 M 28 RTA Negative Negative Negative 
61 1478/12 M 30 TTA Negative Negative Negative 
62 1479/12 F 60 NC Negative Negative Negative 
63 1480/12 M 33 Fall Negative Negative Negative 
64 1481/12 M 25 RTA Negative Negative Negative 
65 1482/12 F 25 NC Negative Negative Negative 
66 1483/12 M 55 Hanging Negative Negative Negative 
67 1484/12 M 65 NC Negative Negative Negative 
68 1485/12 M 35 NC Negative Negative Negative 
69 1486/12 M 45 NC Negative Negative Negative 
70 1487/12 M 45 Burns Negative Negative Negative 
71 1488/12 M 70 NC Negative Negative Negative 
72 1489/12 M 55 NC Negative Negative Negative 
73 1490/12 M 65 NC Negative Negative Negative 
74 1491/12 M 70 TTA Negative Negative Negative 
75 1492/12 F 42 Poisoning Negative Negative Negative 
76 1493/12 M 30 NC Negative Negative Negative 
77 1494/12 M 65 NC Negative Negative Negative 
78 1495/12 M 25 TTA Negative Negative Negative 
79 1496/12 M  NC Negative Negative Negative 
80 1497/12 M 59 NC Negative Negative Negative 
81 1498/12 F 9 TTA Negative Negative Negative 
82 1500/12 M 35 Hanging Negative Negative Negative 
83 1501/12 M 68 TTA Negative Negative Negative 
84 1502/12 M 27 RTA Negative Negative Negative 
 
 
 
85 1503/12 F 38 RTA Negative Negative Negative 
86 1504/12 M 34 RTA Negative Negative Negative 
87 1505/12 F 30 RTA Negative Negative Negative 
88 1506/12 M 70 Fall Negative Negative Negative 
89 1507/12 M 80 NC Negative Negative Negative 
90 1508/12 M 28 TTA Negative Negative Negative 
91 1509/12 M 27 NC Negative Negative Negative 
92 1510/12 M 21 RTA Negative Negative Negative 
93 1511/12 M 76 RTA Negative Negative Negative 
94 1512/12 M 22 RTA Negative Negative Negative 
95 1513/12 M 72 RTA Negative Negative Negative 
96 1514/12 M 27 RTA Negative Negative Negative 
97 1515/12 M 27 Hanging Negative Negative Negative 
98 1516/12 M 14 Hanging Negative Negative Negative 
99 1517/12 M 37 Fall Negative Negative Negative 
100 1518/12 M 27 RTA Negative Negative Negative 
101 1519/12 M 65 NC Negative Negative Negative 
102 1520/12 M 18 RTA Negative Negative Negative 
103 1521/12 M 68 NC Negative Negative Negative 
104 1522/12 M 33 RTA Negative Negative Negative 
105 1523/12 M 32 Fall Negative Negative Negative 
106 1524/12 M 55 Fall Negative Negative Negative 
107 1525/12 M 32 Poisoning Negative Negative Negative 
108 1526/12 F 28 Poisoning Negative Negative Negative 
109 1527/12 F 24 Hanging Negative Negative Negative 
110 1528/12 M 25 Fall Negative Negative Negative 
111 1529/12 F 28 Hanging Negative Negative Negative 
112 1530/12 M 38 RTA Negative Negative Negative 
113 1531/12 F 26 Poisoning Negative Negative Negative 
 
 
 
114 1532/12 M 10 RTA Negative Negative Negative 
115 1533/12 M 48 RTA Negative Negative Negative 
116 1534/12 M 60 Murder Positive Negative Positive 
117 1535/12 M 50 RTA Negative Negative Negative 
118 1536/12 M 25 Fall Negative Negative Negative 
119 1537/12 M 83 TTA Negative Negative Negative 
120 1538/12 M 40 RTA Negative Negative Negative 
121 1539/12 M 40 RTA Negative Negative Negative 
122 1540/12 M 18 RTA Negative Negative Negative 
123 1541/12 M 70 NC Negative Negative Negative 
124 1542/12 M 45 Murder Negative Negative Negative 
125 1543/12 M 42 NC Negative Negative Negative 
126 1544/12 M 39 Poisoning Negative Negative Negative 
127 1545/12 M 38 Poisoning Negative Negative Negative 
128 1546/12 M 26 RTA Negative Negative Negative 
129 1547/12 M 17 TTA Negative Negative Negative 
130 1548/12 F 33 Poisoning Negative Negative Negative 
131 1549/12 F 23 NC Negative Negative Negative 
132 1550/12 F 56 Snake bite Negative Negative Negative 
133 1551/12 F 48 Snake bite Negative Negative Negative 
134 1552/12 M 19 TTA Negative Negative Negative 
135 1553/12 M 29 RTA Negative Negative Negative 
136 1554/12 M 25 Fall Negative Negative Negative 
137 1555/12 M 48 RTA Negative Negative Negative 
138 1556/12 M 31 RTA Negative Negative Negative 
139 1558/12 M 27 TTA Negative Negative Negative 
140 1559/12 M 35 RTA Negative Negative Negative 
141 1560/12 M 66 RTA Negative Negative Negative 
142 1561/12 M 60 RTA Negative Negative Negative 
 
 
 
143 1562/12 F 28 NC Negative Negative Negative 
144 1565/12 M 23 TTA Negative Negative Negative 
145 1567/12 M 42 RTA Negative Negative Negative 
146 1568/12 M 48 RTA Negative Negative Negative 
147 1571/12 M 18 TTA Negative Negative Negative 
148 1572/12 M 43 TTA Negative Negative Negative 
149 1573/12 M 38 Fall Negative Negative Negative 
150 1574/12 M 43 TTA Negative Negative Negative 
151 1575/12 M 48 RTA Negative Negative Negative 
152 1576/12 M 51 RTA Negative Negative Negative 
153 1577/12 M 22 RTA Negative Negative Negative 
154 1579/12 M 26 Fall Negative Negative Negative 
155 1580/12 M 55 RTA Negative Negative Negative 
156 1581/12 M 40 NC Negative Negative Negative 
157 1582/12 M 55 RTA Negative Negative Negative 
158 1583/12 F 21 RTA Negative Negative Negative 
159 1584/12 F 60 Poisoning Negative Negative Negative 
160 1585/12 M 22 RTA Negative Negative Negative 
161 1587/12 M 41 NC Negative Negative Negative 
162 1588/12 M 26 NC Negative Negative Negative 
163 1589/12 M 30 RTA Negative Negative Negative 
164 1590/12 F 40 RTA Negative Negative Negative 
165 1592/12 M 43 Poisoning Negative Negative Negative 
166 1593/12 M 35 Hanging Negative Negative Negative 
167 1594/12 F 24 RTA Negative Negative Negative 
168 1595/12 F 
2 
Mont
h 
RTA Negative Negative Negative 
169 1597/12 M 57 RTA Negative Negative Negative 
170 1598/12 F 26 RTA Negative Negative Negative 
 
 
 
171 1599/12 M 35 TTA Negative Negative Negative 
172 1602/12 M 45 RTA Negative Negative Negative 
173 1605/12 M 24 RTA Negative Negative Negative 
174 1606/12 M 36 NC Negative Negative Negative 
175 1607/12 M 35 NC Negative Negative Negative 
176 1609/12 M 75 NC Negative Negative Negative 
177 1611/12 M 23 Poisoning Negative Negative Negative 
178 1616/12 M 52 RTA Negative Negative Negative 
179 1619/12 M 50 RTA Negative Negative Negative 
180 1620/12 M 20 Fall Negative Negative Negative 
181 1621/12 M 54 NC Negative Negative Negative 
182 1622/12 M 44 RTA Negative Negative Negative 
183 1626/12 M 55 RTA Negative Negative Negative 
184 1629/12 M 29 TTA Negative Negative Negative 
185 1630/12 F 35 RTA Negative Negative Negative 
186 1632/12 M 65 NC Negative Negative Negative 
187 1633/12 M 19 TTA Negative Negative Negative 
188 1634/12 M 27 RTA Negative Negative Negative 
189 1635/12 M 45 NC Negative Negative Negative 
190 1636/12 M 52 TTA Negative Negative Negative 
191 1640/12 M 57 NC Negative Negative Negative 
192 1647/12 F 35 RTA Negative Negative Negative 
193 1648/12 M 23 RTA Negative Negative Negative 
194 1653/12 M 31 Hanging Negative Negative Negative 
195 1654/12 M 72 RTA Negative Negative Negative 
196 1655/12 M 47 RTA Negative Negative Negative 
197 1656/12 M 22 TTA Negative Negative Negative 
198 1658/12 M 62 Murder Negative Negative Negative 
199 1659/12 M 32 TTA Negative Negative Negative 
 
 
 
200 1663/12 M 28 RTA Negative Negative Negative 
201 1664/12 M 65 Poisoning Negative Negative Negative 
202 1666/12 M 45 RTA Negative Negative Negative 
203 1667/12 M 45 RTA Negative Negative Negative 
204 1668/12 M 72 RTA Negative Negative Negative 
205 1669/12 M 47 TTA Negative Negative Negative 
206 1673/12 M 60 Fall Negative Negative Negative 
207 1674/12 M 42 TTA Negative Negative Negative 
208 1675/12 M 50 Fall Negative Negative Negative 
209 1678/12 M 41 RTA Negative Negative Negative 
210 1679/12 M 27 RTA Negative Negative Negative 
211 1681/12 M 41 NC Negative Negative Negative 
212 1682/12 M 54 RTA Negative Negative Negative 
213 1683/12 F 35 RTA Negative Negative Negative 
214 1686/12 F 18 Hanging Negative Negative Negative 
215 1687/12 M 17 Hanging Negative Negative Negative 
216 1689/12 M 18 RTA Negative Negative Negative 
217 1690/12 M 41 TTA Negative Negative Negative 
218 1694/12 F 22 RTA Negative Negative Negative 
219 1695/12 M 42 TTA Negative Negative Negative 
220 1696/12 M 68 NC Negative Negative Negative 
221 1698/12 M 59 RTA Negative Negative Negative 
222 1700/12 M 26 RTA Negative Negative Negative 
223 1701/12 F 25 Poisoning Negative Negative Negative 
224 1703/12 M 53 TTA Negative Negative Negative 
225 1705/12 M 36 Fall Negative Negative Negative 
226 1707/12 M 35 RTA Negative Negative Negative 
227 1715/12 M 5 Burns Negative Negative Negative 
228 1726/12 M 32 Snake bite Negative Negative Negative 
 
 
 
229 1727/12 M 26 TTA Negative Negative Negative 
230 1728/12 M 39 RTA Negative Negative Negative 
231 1731/12 M 22 RTA Negative Negative Negative 
232 1732/12 M 30 RTA Negative Negative Negative 
233 1733/12 M 17 TTA Negative Negative Negative 
234 1735/12 F 50 RTA Negative Negative Negative 
235 1741/12 F 30 RTA Negative Negative Negative 
236 1745/12 M 40 Murder Positive Negative Positive 
237 1746/12 F 65 RTA Negative Negative Negative 
238 1747/12 M 35 RTA Negative Negative Negative 
239 1752/12 M 19 TTA Negative Negative Negative 
240 1753/12 M 50 Fall Negative Negative Negative 
241 1754/12 M 24 RTA Negative Negative Negative 
242 1755/12 F 27 Hanging Negative Negative Negative 
243 1756/12 F 65 NC Negative Negative Negative 
244 1758/12 M 47 TTA Negative Negative Negative 
245 1759/12 M 49 RTA Negative Negative Negative 
246 1762/12 M 30 RTA Negative Negative Negative 
247 1763/12 M 55 RTA Negative Negative Negative 
248 1767/12 F 78 RTA Negative Negative Negative 
249 1769/12 M 25 NC Negative Negative Negative 
250 1770/12 M 26 Murder Negative Negative Negative 
251 1771/12 M 42 RTA Negative Negative Negative 
252 1772/12 M 13 RTA Negative Negative Negative 
253 1775/12 M 23 RTA Negative Negative Negative 
254 1777/12 M 80 RTA Negative Negative Negative 
255 1778/12 F 17 TTA Negative Negative Negative 
256 1779/12 F 25 Poisoning Negative Negative Negative 
257 1780/12 M 65 RTA Negative Negative Negative 
 
 
 
258 1781/12 M 21 RTA Negative Negative Negative 
259 1782/12 M 21 RTA Negative Negative Negative 
260 1783/12 M 64 RTA Negative Negative Negative 
261 1784/12 M 24 RTA Negative Negative Negative 
262 1788/12 M 31 RTA Negative Negative Negative 
263 1790/12 M 25 Fall Negative Negative Negative 
264 1792/12 M 41 RTA Negative Negative Negative 
265 1793/12 F 70 RTA Negative Negative Negative 
266 1795/12 M 14 RTA Negative Negative Negative 
267 1797/12 M 45 Poisoning Negative Negative Negative 
268 1800/12 M 26 TTA Negative Negative Negative 
269 1801/12 M 24 Murder Negative Negative Negative 
270 1802/12 M 50 RTA Negative Negative Negative 
271 1803/12 M 65 NC Positive Negative Positive 
272 1804/12 M 22 NC Negative Negative Negative 
273 1805/12 M 34 Hanging Negative Negative Negative 
274 1806/12 M 48 Fall Negative Negative Negative 
275 1807/12 M 60 NC Negative Negative Negative 
276 1808/12 M 25 Hanging Negative Negative Negative 
277 1809/12 M 20 TTA Negative Negative Negative 
278 1810/12 M 40 RTA Negative Negative Negative 
279 1811/12 F 65 RTA Negative Negative Negative 
280 1812/12 F 55 Murder Negative Negative Negative 
281 1813/12 M 33 RTA Negative Negative Negative 
282 1814/12 M 24 Hanging Negative Negative Negative 
283 1815/12 M 27 Poisoning Negative Negative Negative 
284 1816/12 M 63 RTA Negative Negative Negative 
285 1817/12 M 35 RTA Negative Negative Negative 
286 1818/12 M 26 Fall Negative Negative Negative 
 
 
 
287 1819/12 F 75 Fall Negative Negative Negative 
288 1820/12 M 23 TTA Negative Negative Negative 
289 1821/12 F 67 TTA Negative Negative Negative 
290 1822/12 M 40 TTA Negative Negative Negative 
291 1823/12 M 50 TTA Negative Negative Negative 
292 1824/12 M 35 TTA Negative Negative Negative 
293 1825/12 M 27 TTA Negative Negative Negative 
294 1826/12 M 45 TTA Negative Negative Negative 
295 1827/12 M 50 NC Negative Negative Negative 
296 1828/12 M 36 TTA Negative Negative Negative 
297 1829/12 M 62 RTA Negative Negative Negative 
298 1830/12 M 72 RTA Negative Negative Negative 
299 1831/12 M 44 RTA Negative Negative Negative 
300 1832/12 M 65 Fall Negative Negative Negative 
301 1833/12 M 66 RTA Negative Negative Negative 
302 1834/12 M 55 RTA Negative Negative Negative 
303 1835/12 M 20 RTA Negative Negative Negative 
304 1836/12 M 30 RTA Negative Negative Negative 
305 1837/12 M 19 Fall Negative Negative Negative 
306 1838/12 M 70 NC Negative Negative Negative 
307 1839/12 M 60 RTA Negative Negative Negative 
308 1840/12 M 24 RTA Negative Negative Negative 
309 1841/12 M 35 TTA Negative Negative Negative 
310 1842/12 M 40 RTA Negative Negative Negative 
311 1843/12 M 31 RTA Negative Negative Negative 
312 1844/12 M 34 RTA Negative Negative Negative 
313 1845/12 M 70 RTA Negative Negative Negative 
314 1846/12 M 36 Poisoning Negative Negative Negative 
315 1847/12 M 33 NC Negative Negative Negative 
 
 
 
316 1848/12 M 60 NC Negative Negative Negative 
317 1849/12 M 70 RTA Negative Negative Negative 
318 1850/12 M 65 NC Negative Negative Negative 
319 1851/12 M 32 NC Negative Negative Negative 
320 1852/12 M 42 TTA Negative Negative Negative 
321 1853/12 M 20 RTA Negative Negative Negative 
322 1854/12 M 50 Fall Negative Negative Negative 
323 1855/12 M 93 TTA Negative Negative Negative 
324 1856/12 M 47 Poisoning Negative Negative Negative 
325 1857/12 M 20 RTA Negative Negative Negative 
326 1858/12 M 30 RTA Negative Negative Negative 
327 1859/12 M 50 TTA Negative Negative Negative 
328 1860/12 M 52 RTA Negative Negative Negative 
329 1861/12 F 20 Fall Negative Negative Negative 
330 1862/12 M 38 RTA Negative Negative Negative 
331 1863/12 M 23 Burns Negative Negative Negative 
332 1864/12 M 60 NC Negative Negative Negative 
333 1865/12 M 26 RTA Negative Negative Negative 
334 1866/12 M 24 RTA Negative Negative Negative 
335 1867/12 M 15 RTA Negative Negative Negative 
336 1868/12 F 53 RTA Negative Negative Negative 
337 1869/12 F 45 RTA Negative Negative Negative 
338 1870/12 M 58 NC Negative Negative Negative 
339 1871/12 M 35 Fall Negative Negative Negative 
340 1872/12 M 11 Fall Negative Negative Negative 
341 1873/12 M 43 Fall Negative Negative Negative 
342 1874/12 M 51 RTA Negative Negative Negative 
343 1875/12 M 39 RTA Negative Negative Negative 
344 1876/12 M 35 RTA Negative Negative Negative 
 
 
 
345 1877/12 M 43 TTA Negative Negative Negative 
346 1878/12 M 21 RTA Negative Negative Negative 
347 1879/12 M 45 NC Negative Negative Negative 
348 1880/12 M 75 NC Negative Negative Negative 
349 1881/12 M 59 NC Negative Negative Negative 
350 1882/12 M 26 Poisoning Negative Negative Negative 
351 1883/12 M 25 Hanging Negative Negative Negative 
352 1884/12 M 32 RTA Negative Negative Negative 
353 1885/12 F 37 RTA Negative Negative Negative 
354 1886/12 M 37 RTA Negative Negative Negative 
355 1887/12 M 76 NC Negative Negative Negative 
356 1888/12 M 35 TTA Negative Negative Negative 
357 1889/12 F 50 RTA Negative Negative Negative 
358 1890/12 M 45 NC Negative Negative Negative 
359 1891/12 M 45 NC Negative Negative Negative 
360 1892/12 M 20 TTA Negative Negative Negative 
361 1893/12 M 34 Murder Negative Negative Negative 
362 1894/12 M 62 NC Negative Negative Negative 
363 1895/12 M 29 Hanging Negative Negative Negative 
364 1896/12 M 42 RTA Negative Negative Negative 
365 1897/12 M 50 NC Negative Negative Negative 
366 1898/12 M 70 NC Negative Negative Negative 
367 1899/12 M 42 RTA Negative Negative Negative 
368 1900/12 M 31 Snake bite Negative Negative Negative 
369 1942/12 M 45 RTA Negative Negative Negative 
370 1973/12 M 21 RTA Negative Negative Negative 
371 1944/12 M 31 RTA Negative Negative Negative 
372 1943/12 M 60 RTA Negative Negative Negative 
373 2116/12 M 50 NC Negative Negative Negative 
 
 
 
374 2101/12 M 3 RTA Negative Negative Negative 
375 2974/12 M 17 Poisoning Negative Negative Negative 
376 2973/12 M 51 NC Negative Negative Negative 
377 2999/12 M 61 RTA Negative Negative Negative 
378 2406/12 F 25 TTA Negative Negative Negative 
379 2993/12 M 61 RTA Negative Negative Negative 
380 1918/12 M 50 NC Negative Negative Negative 
381 2046/12 F 80 NC Negative Negative Negative 
382 2833/12 F 60 NC Negative Negative Negative 
383 3012/12 F 65 Snake bite Negative Negative Negative 
384 2364/12 M 27 RTA Negative Negative Negative 
385 2023/12 M 50 Murder Negative Negative Negative 
386 2918/12 M 44 RTA Negative Negative Negative 
387 2453/12 F 50 Drowning Negative Negative Negative 
388 3011/12 M 42 RTA Negative Negative Negative 
389 3020/12 M 55 Poisoning Negative Negative Negative 
390 2834/12 F 55 NC Negative Negative Negative 
391 2232/12 M 33 Hanging Negative Negative Negative 
392 2141/12 M 35 Fall Negative Negative Negative 
393 3013/12 M 21 RTA Negative Negative Negative 
394 2889/12 M 20 RTA Negative Negative Negative 
395 2890/12 M 52 RTA Negative Negative Negative 
396 2913/12 M 65 RTA Negative Negative Negative 
397 2917/12 M 45 RTA Negative Negative Negative 
398 2975/12 M 25 RTA Negative Negative Negative 
399 2491/12 M 47 NC Negative Negative Negative 
400 2025/12 M 40 NC Negative Negative Negative 
401 2870/12 M 47 NC Negative Negative Negative 
402 2977/12 M 30 RTA Negative Negative Negative 
 
 
 
403 2844/12 M 50 NC Negative Negative Negative 
404 2366/12 M 38 RTA Negative Negative Negative 
405 2184/12 M 50 RTA Negative Negative Negative 
406 2077/12 M 40 RTA Negative Negative Negative 
407 2113/12 M 70 RTA Negative Negative Negative 
408 2137/12 F 35 NC Negative Negative Negative 
409 2405/12 M 70 NC Negative Negative Negative 
410 2215/12 M 18 RTA Negative Negative Negative 
411 2075/12 M 38 NC Negative Negative Negative 
412 2997/12 M 45 NC Negative Negative Negative 
413 2996/12 M 38 RTA Negative Negative Negative 
414 2216/12 F 30 RTA Negative Negative Negative 
415 2976/12 M 26 RTA Negative Negative Negative 
416 2234/12 F 53 RTA Negative Negative Negative 
417 2865/12 M 31 RTA Negative Negative Negative 
418 2401/12 M 40 Fall Negative Negative Negative 
419 2868/12 M 27 RTA Negative Negative Negative 
420 3016/12 M 80 NC Negative Negative Negative 
421 2966/12 M 32 RTA Negative Negative Negative 
422 2903/12 M 55 NC Negative Negative Negative 
423 2902/12 M 63 NC Negative Negative Negative 
424 2492/12 M 24 RTA Negative Negative Negative 
425 2117/12 M 52 Hanging Negative Negative Negative 
426 2406/12 F 83 TTA Negative Negative Negative 
427 2916/12 M 49 NC Negative Negative Negative 
428 288/12 M 59 RTA Negative Negative Negative 
429 2878/12 M 42 Fall Negative Negative Negative 
430 2453/12 M 78 Drowning Negative Negative Negative 
431 2190/12 M 18 RTA Negative Negative Negative 
 
 
 
432 2869/12 M 35 RTA Negative Negative Negative 
433 2965/12 M 29 Fall Negative Negative Negative 
434 2901/12 M 32 RTA Negative Negative Negative 
435 2835/12 M 42 NC Negative Negative Negative 
436 2871/12 M 86 RTA Negative Negative Negative 
437 2935/12 M 45 NC Negative Negative Negative 
438 2420/12 M 70 NC Negative Negative Negative 
439 2290/12 M 55 NC Negative Negative Negative 
440 2213/12 M 62 Fall Negative Negative Negative 
441 2235/12 M 30 RTA Negative Negative Negative 
442 2140/12 M 60 NC Negative Negative Negative 
443 2020/12 M 35 RTA Negative Negative Negative 
444 2169/12 M 23 RTA Negative Negative Negative 
445 2138/12 M 28 RTA Negative Negative Negative 
446 2165/12 M 62 RTA Negative Negative Negative 
447 2168/12 M 45 RTA Negative Negative Negative 
448 2292/12 M 30 Fall Negative Negative Negative 
449 2233/12 M 25 RTA Negative Negative Negative 
450 2970/12 F 27 Poisoning Negative Negative Negative 
451 2978/12 F 60 RTA Negative Negative Negative 
452 2400/12 M 26 Hanging Negative Negative Negative 
453 3000/12 M 60 RTA Negative Negative Negative 
454 3008/12 M 35 NC Negative Negative Negative 
455 3017/12 M 30 Poisoning Negative Negative Negative 
456 3019/12 M 50 TTA Positive Negative Positive 
457 2971/12 M 32 RTA Negative Negative Negative 
458 2979/12 F 2 Poisoning Negative Negative Negative 
459 3008/12 M 60 NC Negative Negative Negative 
460 2073/12 M 54 RTA Negative Negative Negative 
 
 
 
461 2210/12 M 40 RTA Negative Negative Negative 
462 2049/12 F 38 RTA Negative Negative Negative 
463 2090/12 M 37 RTA Negative Negative Negative 
464 2050/12 M 28 RTA Negative Negative Negative 
465 2021/12 M 24 TTA Negative Negative Negative 
466 1920/12 F 60 NC Negative Negative Negative 
467 2013/12 M 40 Fall Negative Negative Negative 
468 1945/12 M 25 RTA Negative Negative Negative 
469 2933/12 F 25 NC Negative Negative Negative 
470 2400/12 M 40 Hanging Negative Negative Negative 
471 2846/12 M 65 NC Negative Negative Negative 
472 2845/12 M 26 NC Negative Negative Negative 
473 2900/12 M 45 NC Negative Negative Negative 
474 1947/12 M 45 RTA Negative Negative Negative 
475 2915/12 M 70 NC Negative Negative Negative 
476 2052/12 M 55 NC Negative Negative Negative 
477 1919/12 M 65 NC Negative Negative Negative 
478 1956/12 M 70 TTA Negative Negative Negative 
479 2142/12 F 42 Poisoning Negative Negative Negative 
480 1922/12 M 30 NC Negative Negative Negative 
481 1925/12 M 65 NC Negative Negative Negative 
482 1914/12 M 30 TTA Negative Negative Negative 
483 1917/12 M 60 NC Negative Negative Negative 
484 1916/12 M 59 NC Negative Negative Negative 
485 1905/12 F 2 RTA Negative Negative Negative 
486 1975/12 M 72 RTA Negative Negative Negative 
 
